



EY Entrepreneur of the year-2013



FROST & SULLIVAN
2013 BEST PRACTICES AWARD
Consumer Strategy Leadership Award, India



Business today/YES bank
Excellence Awards-2013



Date: 25 July 2022

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: APPOINTMENT OF MR. SUJESH VASUDEVAN AS AN ADDITIONAL INDEPENDENT DIRECTOR OF THE COMPANY

Dear Sir/Madam,

We wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Mr. Sujesh Vasudevan (DIN : 08240092) as an “Additional Director (Non-Executive Independent Director)” on the Board of Directors of the Company vide a circular resolution. The appointment shall have effect from July 25, 2022, and shall continue till July 24, 2027, subject to the approval of the Shareholders of the Company.

Further, the details pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”) read with Para A of Part A of Schedule III of the Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, along with the brief profile of Mr. Sujesh Vasudevan is annexed herewith.

Thanking You,

For Eris Lifesciences Limited




Milind Talegaonkar

Company Secretary & Compliance Officer

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013

Annexure

Name of the Director	Mr. Sujesh Vasudevan
Reason for Change (appointment)	Appointment - Additional Independent Director (Non-Executive Director)
Date of appointment and Terms of appointment	July 25, 2022 From July 25, 2022, up to July 24, 2027 (both days inclusive), subject to the approval of the Shareholders of the Company, by means of a special resolution.
Disclosure of relationship between Directors inter-se	None
Brief Profile	<p>Education:</p> <ul style="list-style-type: none"> ➤ Mr. Sujesh Vasudevan is a Harvard Alumni ➤ He holds a degree of Masters in Management Studies, Mumbai ➤ Bachelor of Pharmacy, Mumbai. <p>Experience:</p> <p>He has more than 31 Years of experience in the pharma industry that spans across prescription as well as OTC therapies.</p> <p>He was also associated with:</p> <p>Glenmark as a President – India, Middle East and Africa business for ~10 years; Abbott India as Director - Marketing and Sales for ~ 4 years; and Torrent Pharma as Marketing Head – Acute Divisions for ~6 Years.</p>
Declaration	In accordance with SEBI instructions to Stock Exchanges dated June 14, 2018, we confirm that Mr. Sujesh Vasudevan is not debarred from holding the office of Director of the Company, by virtue of any SEBI order or any other such authority.

Registered & Corporate Office: